JNJ Stock Cash Flow Statements

Johnson & Johnson Quarterly Cash Flow Statements Chart

Quarterly

Annual

Johnson & Johnson Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-29	2025-03-30	2024-12-29	2024-09-29	2024-06-30	2024-03-31	2023-12-31	2023-10-01	2023-07-02	2023-04-02	2022-10-02	2022-07-03	2022-04-03	2022-01-01	2021-10-03	2021-07-04	2021-04-04	2021-01-02	2020-09-27	2020-06-28	2020-03-29	2019-12-29	2019-09-29	2018-12-30	2018-09-30	2018-07-01	2018-04-01	2017-12-31	2017-10-01	2017-07-02	2017-04-02	2016-10-02	2016-07-03	2016-04-03	2016-01-01	2015-09-27	2015-06-28	2015-03-29	2015-01-03	2014-09-28	2014-06-29	2014-03-30	2013-09-29	2013-06-30	2013-03-31	2012-09-30	2012-07-01	2012-04-01	2011-10-02	2010-10-03	2009-09-27

cash flows from operating activities
net earnings	5,537,000,000	10,999,000,000	3,431,000,000	2,694,000,000			4,049,000,000	26,028,000,000			4,458,000,000	4,814,000,000	5,149,000,000	1,799,000,000	3,667,000,000	6,278,000,000	6,197,000,000	7,902,000,000	3,554,000,000	3,626,000,000	5,796,000,000	4,010,000,000	1,753,000,000	3,042,000,000	3,934,000,000	3,954,000,000	4,367,000,000	-10,713,000,000	3,764,000,000	3,827,000,000	4,422,000,000	4,272,000,000	4,162,000,000	4,292,000,000	4,346,000,000	3,358,000,000	4,516,000,000	4,320,000,000	1,607,000,000	4,749,000,000	4,326,000,000	4,727,000,000	2,982,000,000	3,833,000,000	3,497,000,000	2,629,000,000	1,408,000,000	3,910,000,000	3,202,000,000	3,417,000,000	3,345,000,000
adjustments to reconcile net earnings to cash flows from operating activities:
depreciation and amortization of property and intangibles	1,943,000,000	1,772,000,000	1,896,000,000	1,846,000,000	1,782,000,000	1,815,000,000	1,843,000,000	1,829,000,000	1,934,000,000	1,880,000,000	1,685,000,000	1,744,000,000	1,769,000,000	1,423,000,000	1,814,000,000	1,839,000,000	1,894,000,000	2,099,000,000	1,818,000,000	1,726,000,000	1,747,000,000	1,816,000,000	1,727,000,000	1,735,000,000	1,731,000,000	1,717,000,000	1,746,000,000	1,869,000,000	1,711,000,000	1,150,000,000	912,000,000	908,000,000	900,000,000	891,000,000	1,041,000,000	929,000,000	889,000,000	895,000,000	842,000,000	939,000,000	952,000,000	1,013,000,000	976,000,000	990,000,000	1,036,000,000	1,005,000,000	852,000,000	773,000,000	783,000,000	725,000,000	675,000,000
stock based compensation	410,000,000	288,000,000	238,000,000	295,000,000	341,000,000	302,000,000	178,000,000	296,000,000	382,000,000	306,000,000	281,000,000	366,000,000	278,000,000	218,000,000	259,000,000	354,000,000	307,000,000	290,000,000	256,000,000	326,000,000	263,000,000	160,000,000	245,000,000	156,000,000	242,000,000	312,000,000	268,000,000	204,000,000	236,000,000	293,000,000	229,000,000	225,000,000	274,000,000	205,000,000	201,000,000	203,000,000	270,000,000	204,000,000	228,000,000	206,000,000	242,000,000	198,000,000	161,000,000	229,000,000	194,000,000	146,000,000	196,000,000	173,000,000	145,000,000	169,000,000	158,000,000
asset write-downs	0	30,000,000	26,000,000	0	194,000,000	185,000,000	475,000,000	432,000,000	-38,000,000	426,000,000	40,000,000	137,000,000	610,000,000	252,000,000	938,000,000	12,000,000	14,000,000	791,000,000	165,000,000	22,000,000	11,000,000	77,000,000	30,000,000	32,000,000	1,199,000,000			486,000,000	39,000,000	233,000,000	37,000,000	0	105,000,000	82,000,000	-84,000,000	356,000,000			365,000,000	87,000,000	135,000,000	37,000,000	178,000,000	0	69,000,000
charges for purchase of in-process research and development assets	76,000,000	16,000,000
net gain on sale of assets/businesses	1,000,000	-75,000,000	-1,000,000	-2,000,000			0	-70,000,000	-39,000,000	-8,000,000	0	-45,000,000	-168,000,000	221,000,000	0	-21,000,000	-580,000,000	-557,000,000	0				-46,000,000		0			-780,000,000	-474,000,000			-91,000,000			711,000,000	-240,000,000	-996,000,000	-38,000,000	-247,000,000	-2,004,000,000
deferred tax provision	825,000,000	2,172,000,000	-16,000,000	90,000,000	-695,000,000	-1,562,000,000	-2,412,000,000	560,000,000	-799,000,000	-1,543,000,000	-139,000,000	-1,423,000,000	-926,000,000	901,000,000	-1,879,000,000	45,000,000	-730,000,000	-1,841,000,000	190,000,000	-482,000,000	54,000,000	-350,000,000	-1,432,000,000	-1,069,000,000	338,000,000	-329,000,000	44,000,000	2,813,000,000	-335,000,000	-45,000,000	-27,000,000	100,000,000	-278,000,000	393,000,000	-574,000,000	-51,000,000	-261,000,000	545,000,000	-567,000,000	-296,000,000	98,000,000	495,000,000	-316,000,000	-273,000,000	365,000,000	187,000,000	-1,068,000,000	557,000,000	-345,000,000
credit losses and accounts receivable allowances	7,000,000	-4,000,000	22,000,000							1,000,000	-11,000,000	-9,000,000	6,000,000	43,000,000	-8,000,000	-39,000,000	-13,000,000	-122,000,000	-43,000,000
changes in assets and liabilities, net of effects from acquisitions and divestitures:
increase in accounts receivable	-1,357,000,000	-926,000,000	853,000,000	-96,000,000	-884,000,000	-279,000,000	227,000,000	-252,000,000	-545,000,000	-54,000,000	-205,000,000	-959,000,000	-427,000,000		-252,000,000	38,000,000	-1,604,000,000		80,000,000			376,000,000	-329,000,000	-145,000,000	-51,000,000	-510,000,000	-479,000,000	-333,000,000	176,000,000	-380,000,000	-96,000,000	362,000,000	-709,000,000	-389,000,000	-155,000,000	276,000,000	-421,000,000	-765,000,000	-34,000,000	185,000,000	-158,000,000	-426,000,000			-434,000,000			-215,000,000	87,000,000	-30,000,000	164,000,000
increase in inventories	-510,000,000	-146,000,000	-90,000,000	-299,000,000	-391,000,000	-348,000,000	124,000,000	-706,000,000	-217,000,000	-524,000,000	-620,000,000	-657,000,000	-600,000,000	-1,349,000,000	-360,000,000	-123,000,000	-695,000,000	-464,000,000	-147,000,000	-478,000,000	-159,000,000		-1,000,000		-286,000,000	-169,000,000	-322,000,000		228,000,000	-53,000,000	-368,000,000	35,000,000	-253,000,000	-190,000,000	470,000,000	-182,000,000	-261,000,000	-276,000,000	649,000,000	-493,000,000	-93,000,000	-512,000,000	-252,000,000	-259,000,000	-288,000,000	25,000,000	-169,000,000	-449,000,000	-167,000,000	-109,000,000	89,000,000
(decrease) / increase in accounts payable and accrued liabilities
(increase)/decrease in other current and non-current assets	-4,877,000,000	-1,317,000,000					-2,114,000,000	-222,000,000	-229,000,000	-915,000,000																						251,000,000
decrease in other current and non-current liabilities	583,000,000	-6,509,000,000									-1,552,000,000					-248,000,000	-902,000,000			-500,000,000	-329,000,000																					-428,000,000
net cash flows from operating activities	3,878,000,000	4,174,000,000	6,983,000,000	7,993,000,000	5,633,000,000	3,657,000,000	7,863,000,000	7,489,000,000	4,182,000,000	3,257,000,000	6,284,000,000	5,581,000,000	3,979,000,000	3,516,000,000	8,290,000,000	5,314,000,000	4,074,000,000	8,217,000,000	8,383,000,000	3,452,000,000	3,358,000,000	6,398,000,000	7,527,000,000	6,244,000,000	6,272,000,000	6,079,000,000	3,606,000,000	6,105,000,000	6,266,000,000	5,772,000,000	2,913,000,000	5,361,000,000	4,990,000,000	1,763,000,000	4,570,000,000	6,125,000,000	5,200,000,000	2,872,000,000	5,173,000,000	4,654,000,000	5,529,000,000	3,923,000,000	5,947,000,000	5,051,000,000	2,277,000,000	4,497,000,000	4,728,000,000	2,795,000,000	4,622,000,000	5,034,000,000	5,094,000,000
cash flows from investing activities
additions to property, plant and equipment	-1,043,000,000	-795,000,000	-1,612,000,000	-1,029,000,000	-976,000,000	-807,000,000	-1,589,000,000	-967,000,000	-1,124,000,000	-863,000,000	-952,000,000	-863,000,000	-607,000,000	-1,772,000,000	-747,000,000	-813,000,000	-677,000,000	-1,628,000,000	-737,000,000	-662,000,000	-625,000,000	-1,260,000,000	-745,000,000	-1,318,000,000	-819,000,000	-875,000,000	-658,000,000	-1,240,000,000	-790,000,000	-689,000,000	-560,000,000	-737,000,000	-757,000,000	-639,000,000	-1,129,000,000	-789,000,000	-765,000,000	-543,000,000	-1,245,000,000	-751,000,000	-837,000,000	-630,000,000	-809,000,000	-771,000,000	-586,000,000	-682,000,000	-598,000,000	-502,000,000	-711,000,000	-528,000,000	-519,000,000
proceeds from the disposal of assets/businesses	53,000,000	279,000,000	52,000,000	50,000,000	363,000,000	210,000,000	121,000,000	121,000,000	76,000,000	40,000,000	8,000,000	66,000,000	248,000,000	-123,000,000	12,000,000	51,000,000	603,000,000	611,000,000	13,000,000	70,000,000	17,000,000	162,000,000	85,000,000	2,308,000,000	25,000,000	850,000,000	20,000,000	1,106,000,000	601,000,000	94,000,000	31,000,000	188,000,000	660,000,000	25,000,000	-353,000,000	427,000,000	1,083,000,000	110,000,000	-1,017,000,000	3,908,000,000
acquisitions, net of cash acquired			-1,000,000	-338,000,000	-12,996,000,000	-1,811,000,000					1,000,000	-271,000,000	-252,000,000					889,000,000	0	-10,000,000	-939,000,000	-248,000,000	-216,000,000	-2,000,000	-675,000,000	-140,000,000	-82,000,000	-505,000,000	-574,000,000	-29,220,000,000	-4,852,000,000	-3,320,000,000	-725,000,000	-5,000,000	-4,276,000,000	0	0	-233,000,000	-663,000,000				-645,000,000	-6,000,000	-168,000,000	13,236,000,000			-420,000,000	-398,000,000	-1,046,000,000
acquired in-process research and development assets / related milestones
purchases of investments	-180,000,000	-251,000,000	-262,000,000	-280,000,000	-554,000,000	-630,000,000	-925,000,000	-293,000,000	-5,914,000,000	-3,774,000,000	-9,115,000,000	-13,030,000,000	-9,018,000,000	-13,541,000,000	-6,579,000,000	-6,270,000,000	-5,994,000,000	-14,151,000,000	-7,692,000,000	-6,487,000,000	-2,064,000,000	-1,236,000,000	-1,167,000,000	-1,471,000,000	-3,204,000,000	-403,000,000	-548,000,000	-355,000,000	-571,000,000	-677,000,000	-4,550,000,000	-10,166,000,000	-7,449,000,000	-10,062,000,000	-5,184,000,000	-7,953,000,000	-13,651,000,000	-7,162,000,000	-15,044,000,000	-8,432,000,000	-11,925,000,000	-5,427,000,000	-5,014,000,000	-5,018,000,000	-3,551,000,000	-3,626,000,000	-2,813,000,000	-2,398,000,000	-8,624,000,000	-3,984,000,000	-2,437,000,000
sales of investments	735,000,000	218,000,000	290,000,000	466,000,000	727,000,000	979,000,000	3,603,000,000	3,910,000,000	4,111,000,000	7,766,000,000	8,690,000,000	11,331,000,000	6,303,000,000	24,800,000,000	4,356,000,000	7,220,000,000	5,233,000,000	18,421,000,000	4,168,000,000	873,000,000	1,544,000,000	928,000,000	327,000,000	3,127,000,000	419,000,000	402,000,000	341,000,000	606,000,000	191,000,000	18,326,000,000	8,994,000,000	11,662,000,000	9,630,000,000	9,145,000,000	12,613,000,000	7,338,000,000	9,779,000,000	6,050,000,000	19,573,000,000	6,354,000,000	4,145,000,000	4,077,000,000	4,894,000,000	5,197,000,000	2,800,000,000	2,251,000,000	3,283,000,000	6,600,000,000	7,856,000,000	2,869,000,000	2,226,000,000
credit support agreements activity	-2,980,000,000	296,000,000	818,000,000	-731,000,000	-170,000,000	1,600,000,000	-2,046,000,000	-119,000,000	-956,000,000	158,000,000	-295,000,000	239,000,000	-249,000,000	-945,000,000	255,000,000	-310,000,000	751,000,000
other	-36,000,000	-30,000,000	-72,000,000	-16,000,000	-81,000,000	-5,000,000	104,000,000	-111,000,000	31,000,000	-12,000,000	-38,000,000	-111,000,000	-59,000,000	185,000,000	-16,000,000	-297,000,000	-101,000,000	8,000,000	-24,000,000	-235,000,000	-257,000,000	-28,000,000	71,000,000	-416,000,000	-15,000,000	-35,000,000	2,000,000	-117,000,000	-37,000,000	-81,000,000	1,000,000	1,000,000	-37,000,000	-1,000,000	-88,000,000	-24,000,000	0	-11,000,000	44,000,000	-53,000,000	-13,000,000	-81,000,000	-24,000,000	-12,000,000	-4,000,000	4,000,000	-6,000,000	-2,000,000	-269,000,000	-49,000,000	-79,000,000
net cash used by investing activities	-18,264,000,000	-297,000,000									-1,701,000,000	-2,639,000,000	-3,634,000,000	-9,048,000,000	-2,719,000,000	-419,000,000	-185,000,000	4,239,000,000	-4,819,000,000	-7,522,000,000	-581,000,000	-1,344,000,000	-1,645,000,000	2,228,000,000	-4,269,000,000	-201,000,000	-925,000,000	-505,000,000	-1,180,000,000	-12,247,000,000	-936,000,000	-2,372,000,000	1,322,000,000	-1,537,000,000	1,583,000,000	-1,001,000,000	-3,554,000,000	-1,789,000,000	1,648,000,000	735,000,000	-8,092,000,000	-2,026,000,000	-1,553,000,000			11,398,000,000			-1,590,000,000	-1,875,000,000	-1,855,000,000
cash flows from financing activities
dividends to shareholders	-3,129,000,000	-2,989,000,000	-2,984,000,000	-2,985,000,000	-2,985,000,000	-2,869,000,000	-2,865,000,000	-2,871,000,000	-3,092,000,000	-2,942,000,000	-2,970,000,000	-2,971,000,000	-2,787,000,000	-3,441,000,000	-2,791,000,000	-2,791,000,000	-2,659,000,000	-3,209,000,000	-2,659,000,000	-2,659,000,000	-2,505,000,000	-2,500,000,000	-2,499,000,000	-2,411,000,000	-2,415,000,000	-2,415,000,000	-2,253,000,000	-2,256,000,000	-2,254,000,000	-2,262,000,000	-2,171,000,000	-2,185,000,000	-2,197,000,000	-2,069,000,000	-2,520,000,000	-2,076,000,000	-2,079,000,000	-1,946,000,000	-2,361,000,000	-1,967,000,000	-1,978,000,000	-1,867,000,000	-1,862,000,000	-1,856,000,000	-1,706,000,000	-1,683,000,000	-1,676,000,000	-1,565,000,000	-1,558,000,000	-1,484,000,000	-1,351,000,000
repurchase of common stock	0	-2,127,000,000	-282,000,000	-539,000,000	-136,000,000	-1,475,000,000	-216,000,000	-920,000,000	-381,000,000	-3,537,000,000	-2,165,000,000	-973,000,000	-1,577,000,000	-3,575,000,000	-391,000,000	-631,000,000	-1,438,000,000	-556,000,000	-483,000,000	-706,000,000	-1,711,000,000	-426,000,000	-1,628,000,000	-3,808,000,000	-471,000,000	-145,000,000	-1,444,000,000	-815,000,000	-311,000,000	-1,890,000,000	-3,342,000,000	-2,203,000,000	-2,362,000,000	-2,389,000,000	-5,585,000,000	-300,000,000	-896,000,000	-2,198,000,000	-909,000,000	-2,415,000,000	-1,192,000,000	-774,000,000				0	-12,852,000,000	-67,000,000	-743,000,000	-732,000,000	-49,000,000
proceeds from short-term debt	565,000,000	8,784,000,000	3,293,000,000	-1,992,000,000	8,713,000,000	5,263,000,000	1,281,000,000	241,000,000	1,127,000,000	11,094,000,000	2,728,000,000	1,352,000,000	3,019,000,000	14,851,000,000	785,000,000	475,000,000	23,000,000	-1,338,000,000	618,000,000	2,707,000,000	10,000,000	-109,000,000	133,000,000	40,000,000	13,000,000	1,000,000	26,000,000	-3,891,000,000	2,125,000,000	1,916,000,000	719,000,000	31,000,000	23,000,000	95,000,000	-1,996,000,000	1,083,000,000	435,000,000	589,000,000	1,787,000,000	-1,039,000,000	1,390,000,000	278,000,000	88,000,000	1,207,000,000	475,000,000	1,088,000,000	971,000,000	1,547,000,000	3,630,000,000	940,000,000	821,000,000
repayment of short-term debt	-2,938,000,000	-2,120,000,000	-1,109,000,000	-4,439,000,000	-3,025,000,000	-890,000,000	-1,328,000,000	-8,034,000,000	-8,223,000,000	-5,388,000,000	-2,607,000,000	-1,345,000,000	-856,000,000	-5,729,000,000	-132,000,000	-214,000,000	-475,000,000	-880,000,000	-293,000,000	1,000,000	-18,000,000
proceeds from long-term debt, net of issuance costs	0	9,138,000,000	0	1,000,000	6,657,000,000	2,000,000			0	7,674,000,000	-1,000,000			-1,000,000	2,000,000	0	1,000,000	-7,426,000,000	7,430,000,000			2,000,000	0	-1,000,000	3,000,000	1,000,000	2,000,000	4,527,000,000	1,000,000	0	4,464,000,000	0	4,516,000,000	7,435,000,000
repayment of long-term debt	-3,000,000	-751,000,000	-649,000,000	-1,000,000	-802,000,000	-1,000,000	-1,049,000,000	-1,000,000	-1,000,000	-500,000,000	-1,000,000	0	-2,132,000,000	-682,000,000	-1,000,000	-450,000,000	-1,001,000,000	-1,240,000,000	-551,000,000	0	-11,000,000
proceeds from the exercise of stock options/employee withholding tax on stock awards	107,000,000	450,000,000	124,000,000	424,000,000	95,000,000	195,000,000	187,000,000	653,000,000	265,000,000	-11,000,000	87,000,000	499,000,000	321,000,000	521,000,000	265,000,000	307,000,000	236,000,000	114,000,000	214,000,000	376,000,000	332,000,000	374,000,000	117,000,000	469,000,000	318,000,000	96,000,000	66,000,000	208,000,000	135,000,000	317,000,000	402,000,000	183,000,000
settlement of convertible debt acquired from shockwave				0
net cash from financing activities	-5,665,000,000	10,422,000,000
effect of exchange rate changes on cash and cash equivalents								-168,000,000	-97,000,000	28,000,000	-286,000,000	-161,000,000	16,000,000	-187,000,000	-92,000,000	45,000,000	-78,000,000	-43,000,000	31,000,000	71,000,000	-237,000,000	74,000,000	-116,000,000	-32,000,000	-39,000,000	-274,000,000	104,000,000	40,000,000	106,000,000	81,000,000	110,000,000	21,000,000	-69,000,000	81,000,000	967,000,000	-299,000,000	-492,000,000	-391,000,000	-1,298,000,000	-91,000,000	-55,000,000	-45,000,000	22,000,000	-53,000,000	-153,000,000	54,000,000	-89,000,000	57,000,000	-157,000,000	165,000,000	173,000,000
(decrease) / increase in cash and cash equivalents
cash and cash equivalents, beginning of period											0	0	14,487,000,000		0	0	13,985,000,000		0	0	17,305,000,000		0		0	0	17,824,000,000		0	0	18,972,000,000	0	0	13,732,000,000		0	0	14,523,000,000		0	0	20,927,000,000	0	0	14,911,000,000	0	0	24,542,000,000	0	0	0
cash and cash equivalents, end of period								-1,455,000,000			372,000,000	520,000,000	10,463,000,000		3,272,000,000	1,661,000,000	12,671,000,000		7,791,000,000	-4,356,000,000	15,530,000,000		1,873,000,000		-1,513,000,000	2,930,000,000	14,639,000,000		3,123,000,000	-8,311,000,000	20,909,000,000	-435,000,000	4,779,000,000	13,861,000,000		3,000,000,000	-1,349,000,000	11,988,000,000		-418,000,000	-5,486,000,000	19,722,000,000	-103,000,000	2,452,000,000	14,855,000,000	1,444,000,000	-16,225,000,000	30,267,000,000	643,000,000	1,625,000,000	170,000,000
decrease in accounts payable and accrued liabilities		-2,126,000,000				-2,483,000,000			1,511,000,000	-2,572,000,000		1,647,000,000	-2,817,000,000			-1,714,000,000	-2,336,000,000			204,000,000	-2,523,000,000					1,637,000,000	-1,686,000,000			829,000,000	-2,030,000,000	-173,000,000	1,286,000,000	-2,333,000,000		645,000,000	248,000,000	-2,451,000,000			409,000,000	-1,004,000,000			-1,459,000,000			-1,331,000,000	344,000,000	167,000,000	67,000,000
acquired in-process research and development assets		-14,000,000
form 10-q
charges for acquired in-process research and development assets
gain on kenvue separation							0
increase in accounts payable and accrued liabilities			-1,092,000,000				1,682,000,000															1,787,000,000		3,220,000,000				2,386,000,000
decrease/(increase) in other current and non-current assets			768,000,000	-2,782,000,000	532,000,000	3,199,000,000								-1,395,000,000	667,000,000																								-7,000,000
increase/(decrease) in other current and non-current liabilities							3,328,000,000	-1,147,000,000					110,000,000																	-98,000,000	420,000,000						15,000,000	1,021,000,000					1,186,000,000
net cash (used by)/from investing activities																																													-1,403,000,000
48
charge for purchase of in-process research and development assets
(decrease)/increase in other current and non-current liabilities				2,742,000,000	-2,641,000,000	-427,000,000								-41,000,000																		-522,000,000	-481,000,000	-385,000,000											-192,000,000	-15,000,000
purchases of in-process research and development assets
net cash (used by) / from investing activities
proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to kenvue at separation
proceeds from kenvue initial public offering								0
cash transferred to kenvue at separation
increase/(decrease) in accounts payable and accrued liabilities																																														321,000,000
net cash flows from financing activities					7,544,000,000	546,000,000
net earnings/						3,255,000,000
net cash (used by)/ from investing activities						-464,000,000
net cash from/(used) by investing activities
net cash from (used by) investing activities
net cash used by financing activities											-3,925,000,000	-2,261,000,000	-4,385,000,000	1,740,000,000	-2,207,000,000	-3,279,000,000	-5,125,000,000	-13,571,000,000	4,196,000,000	-357,000,000	-4,315,000,000	-4,072,000,000	-3,893,000,000	-6,389,000,000	-3,477,000,000	-2,674,000,000	-5,970,000,000	-3,537,000,000	-2,069,000,000	-1,917,000,000	-150,000,000	-3,445,000,000	-1,464,000,000	-178,000,000	-996,000,000	-1,825,000,000	-2,503,000,000	-3,227,000,000	795,000,000	-5,716,000,000	-2,868,000,000	-3,057,000,000	-4,519,000,000	-1,977,000,000	-777,000,000	-14,505,000,000	-3,403,000,000	-1,183,000,000	-2,232,000,000	-1,699,000,000	-3,242,000,000
increase/(decrease) in cash and cash equivalents								-1,455,000,000										-1,158,000,000														-435,000,000	4,779,000,000	129,000,000									-103,000,000
cash and cash equivalents from continuing operations, beginning of period
cash and cash equivalents from discontinued operations, beginning of period
cash and cash equivalents beginning of period								0	0	14,127,000,000
cash and cash equivalents from continuing operations, end of period
cash and cash equivalents from discontinued operations, end of period
acquisitions
fair value of assets acquired											-1,000,000	366,000,000	255,000,000						0	37,000,000	1,136,000,000		117,000,000		712,000,000	215,000,000	119,000,000		333,000,000	30,911,000,000	5,250,000,000	3,350,000,000	737,000,000	7,000,000		0	1,000,000	476,000,000					820,000,000	6,000,000	186,000,000				441,000,000	412,000,000	1,674,000,000
fair value of liabilities assumed
net cash paid for acquisitions											-1,000,000	271,000,000	252,000,000						0	10,000,000	939,000,000		216,000,000		675,000,000	140,000,000	82,000,000		574,000,000	29,220,000,000	4,852,000,000	3,320,000,000	725,000,000	5,000,000									645,000,000						420,000,000	398,000,000	1,046,000,000
net cash from/(used by) financing activities									-5,991,000,000	6,138,000,000
net (loss)/earnings										-68,000,000
increase in other current and non-current liabilities										6,328,000,000																	595,000,000																					89,000,000	547,000,000
net cash from/(used by) investing activities										3,315,000,000
increase/(decrease) in cash, cash equivalents and restricted cash										12,738,000,000
cash, cash equivalents and restricted cash, end of period										26,865,000,000
decrease in other current and non-current assets											1,036,000,000	2,532,000,000	995,000,000				2,522,000,000																		-968,000,000
(decrease)/increase in cash and cash equivalents											372,000,000																-3,185,000,000	2,103,000,000	3,123,000,000										6,318,000,000	-418,000,000					-56,000,000					1,625,000,000
fair value of liabilities assumed and noncontrolling interests											0	-95,000,000	-3,000,000						0	-27,000,000	-197,000,000		99,000,000		-37,000,000	-75,000,000	-37,000,000		241,000,000	-1,691,000,000	-398,000,000	-30,000,000	-12,000,000	-2,000,000		0	-1,000,000	-243,000,000					-175,000,000	0	-18,000,000
decrease in cash and cash equivalents													-4,024,000,000				-1,314,000,000			-4,356,000,000	-1,775,000,000		1,873,000,000		-1,513,000,000											3,000,000,000	-1,349,000,000	-2,535,000,000				-1,205,000,000				1,444,000,000			643,000,000
contingent consideration reversal																			-165,000,000	0	-983,000,000
(increase)/decrease in accounts receivable																																											-324,000,000
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
supplemental cash flow data
cash paid during the year for:
interest
interest, net of amount capitalized
income taxes
increase in cash and cash equivalents																															1,937,000,000																	5,725,000,000			170,000,000
increase in other current and non-current assets																		19,000,000	-935,000,000			-973,000,000	781,000,000	629,000,000	-637,000,000	640,000,000	-907,000,000	144,000,000	-14,000,000	32,000,000	-573,000,000			-802,000,000				-562,000,000			-412,000,000	-152,000,000	34,000,000	171,000,000	-608,000,000	-761,000,000	725,000,000	-754,000,000	14,000,000	394,000,000	-7,000,000
(decrease)/increase in accounts payable and accrued liabilities																																							824,000,000
proceeds from credit support agreements																			-547,000,000	-1,071,000,000	1,743,000,000
accounts receivable allowances and credit losses																					22,000,000
(increase) / decrease in accounts receivable																					-812,000,000
decrease / (increase) in other current and non-current assets																					271,000,000
decrease/(increase) in accounts receivable																																														-61,000,000
gain on sale of assets/businesses
accounts receivable allowances																						-5,000,000	-16,000,000	-28,000,000	13,000,000	4,000,000	-20,000,000	-42,000,000	35,000,000	37,000,000	-13,000,000	-6,000,000	-3,000,000	-1,000,000	-13,000,000	-3,000,000	26,000,000	-21,000,000	72,000,000	-17,000,000	-12,000,000	-25,000,000	-3,000,000	-18,000,000	-11,000,000	3,000,000	41,000,000	42,000,000	12,000,000	-16,000,000	-13,000,000
(increase)/decrease in inventories
increase / (decrease) in other current and non-current liabilities
retirement of short-term debt																							-75,000,000	-114,000,000	68,000,000	51,000,000	-2,484,000,000	-394,000,000	-756,000,000	15,000,000	-195,000,000	761,000,000	-515,000,000	-4,172,000,000	-1,087,000,000	-585,000,000	-152,000,000	-193,000,000	669,000,000	-647,000,000	209,000,000	-1,275,000,000	-142,000,000	-570,000,000	-704,000,000	-1,000,000,000	-2,990,000,000	-1,790,000,000	-3,850,000,000	-1,792,000,000	-2,681,000,000
retirement of long-term debt																							-3,000,000	-645,000,000	-901,000,000	-1,000,000	-8,000,000	-753,000,000	-1,009,000,000	-13,000,000	-2,000,000	-17,000,000	-922,000,000	-14,000,000	-2,196,000,000	-6,000,000	-5,000,000	-16,000,000	1,719,000,000	-10,000,000	-1,756,000,000	-21,000,000	-27,000,000	-1,503,000,000	-1,000,000	-786,000,000	20,000,000	-30,000,000	-7,000,000	-9,000,000	-208,000,000
net gain on sale of assets
venezuela adjustments																																							33,000,000	26,000,000
decrease/(increase) in inventories
proceeds from the exercise of stock options/excess tax benefits																																		936,000,000		59,000,000	194,000,000	584,000,000	-111,000,000	358,000,000	462,000,000	586,000,000	429,000,000	719,000,000	1,123,000,000	669,000,000	268,000,000	880,000,000	229,000,000	299,000,000	226,000,000
proceeds from long-term debt																																			12,001,000,000	0	0	3,000,000	58,000,000	4,000,000	-3,000,000	16,000,000	45,000,000	0	6,000,000	10,000,000	4,000,000	2,000,000	67,000,000		0
changes in assets and liabilities, net of effects from acquisitions:
net fair value of acquisitions																																				0	0	233,000,000					645,000,000	6,000,000	168,000,000
net gain on equity investment transactions																																											21,000,000
raw materials and supplies																																								-86,000,000
goods in process																																								167,000,000
finished goods																																								183,000,000
total inventories																																								264,000,000
venezuela currency devaluation																																											0	0	108,000,000
proceeds from the disposal of assets																																										35,000,000	45,000,000	41,000,000	106,000,000	215,000,000	332,000,000	358,000,000	578,000,000	215,000,000	0
noncontrolling interest
johnson & johnson and subsidiariesconsolidated statements of cash flows
supplemental schedule of non-cash investing and financing activities
issuance of common stock associated with the acquisition of synthes, inc.
less: issuance of common stock associated with the acquisition of synthes, inc.
intangible asset write-downs																																														679,000,000
reissuance of common stock
fair value of liabilities assumed and non-controlling interests																																																	-21,000,000
cash flow from operating activities
net cash flows from investing activities																																																4,056,000,000
decrease in deferred tax provision																																																		40,000,000
net cash(used by)/from financing activities
purchased in-process research and development
decrease/(increase) in deferred tax provision																																																			-104,000,000
adjustment to reconcile net earnings to cash flows from operating activities:
adjustments to reconcile net earnings to cash flow:
net cash provided/(used) by investing activities
proceeds from the exercise of stock options and related excess tax benefits

We provide you with 20 years of cash flow statements for Johnson & Johnson stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Johnson & Johnson stock. Explore the full financial landscape of Johnson & Johnson stock with our expertly curated income statements.

The information provided in this report about Johnson & Johnson stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.